About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement

By: via GlobeNewswire

SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the “Supplement”) from Chemokine Pte. Ltd. (“Chemokine”), a Singapore-based biotech company focused on molecular supplements and gene modulating formulations.

EUDA and its subsidiaries will market and sell the Supplement under the brand name, Euda Helixé, initially in Singapore, Malaysia, and China before expanding it to other markets in the future. The addition of the Supplement will further reinforce EUDA’s wellness product portfolio as it drives the transformation of the health and wellness landscape in the region.

The Supplement is an advanced formulation designed to modulate gene expression by activating beneficial genes while silencing harmful ones. Leveraging cutting-edge epigenetic technology, the Supplement enhances metabolism, boosts vitality, supports longevity, and is positioned as a foundational pillar in EUDA’s growing wellness product suite.

The Supplement builds on prior scientific advancements and proven formulation platforms to deliver molecular-level wellness support. The Supplement combines premium-grade ingredients including:

· Deer placenta
· L-Glutathione
· Astaxanthin
· Marine collagen
· Sea-Buckthorn oil
· Grape seed oil
· New Zealand refined avocado oil

Its capsule delivery system ensures active ingredients survive stomach acid and are released where absorption is maximized, enhancing efficacy.

Key Benefits of the Supplement

  1.    Gene-activated metabolic enhancement

  2.    Sustained energy and vigor via time-release delivery

  3.    Collagen-based youthfulness and skin regeneration

  4.    Longevity support through stem cell regeneration pathways

Chemokine was founded by Professor Kah Meng Lim, a molecular medicine researcher with deep scientific roots. Prof. Lim earned his Ph.D. in Molecular Medicine from the National University of Singapore and spent years in research roles under Singapore’s national R&D agency, A*STAR. His work bridges academic science and consumer health innovation, and he is widely respected for translating complex biological discoveries into practical health applications.

Mr. Alfred Lim, CEO of EUDA, commented, “Securing exclusive distribution rights for such a special product will reinforce our portfolio of wellness product offerings and further diversify our revenue streams. The Supplement positions EUDA at the forefront of molecular precision wellness, leveraging breakthrough gene activation technology. With our strong regional ecosystem and distribution capabilities, we believe that it is possible to generate sales of about 500,000 bottles over the next 12 months.”

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward Looking Statements 

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 

Contact:

Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com


More News

View More
JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall?
Via MarketBeat
Topics Earnings
Tickers BAC JPM KBWB
Snap-on Incorporated: Snap It Up Quick, New Highs Will Come Soon
Via MarketBeat
Tickers SNA
As Global Renewables Surpass Coal, This ETF Offers Smart Exposure
Via MarketBeat
Topics ETFs Energy
Tickers BE FSLR ICLN
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Via MarketBeat
Tickers JNJ KVUE PTGX
Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
Via MarketBeat
Topics Artificial Intelligence
Tickers TSLA

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
+0.00 (0.00%)
AAPL  252.29
+0.00 (0.00%)
AMD  233.08
+0.00 (0.00%)
BAC  51.28
+0.00 (0.00%)
GOOG  253.79
+0.00 (0.00%)
META  716.91
+0.00 (0.00%)
MSFT  513.58
+0.00 (0.00%)
NVDA  183.16
+0.00 (0.00%)
ORCL  291.31
+0.00 (0.00%)
TSLA  439.31
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.